Omnicell, Inc., provides medication management automation solutions and adherence tools for health care systems and pharmacies in the United States and internationally. The company is headquartered in Mountain View, California.
| Revenue (TTM) | $1.25B |
| Gross Profit (TTM) | $562.73M |
| EBITDA | $97.78M |
| Operating Margin | 10.40% |
| Return on Equity | 3.06% |
| Return on Assets | 1.94% |
| Revenue/Share (TTM) | $27.49 |
| Book Value | $27.63 |
| Price-to-Book | 1.32 |
| Price-to-Sales (TTM) | 1.36 |
| EV/Revenue | 1.28 |
| EV/EBITDA | 11.21 |
| Quarterly Earnings Growth (YoY) | 333.30% |
| Quarterly Revenue Growth (YoY) | 7.50% |
| Shares Outstanding | $45.61M |
| Float | $44.37M |
| % Insiders | 2.24% |
| % Institutions | 108.65% |
Volatility is currently contracting
OMCL raised its 2026 EPS outlook after a strong second quarter, but rising memory-chip costs and delayed hospital purchases could test margins.
Omnicell's 20.1% monthly slide reflects booking uncertainty, margin pressure and refresh-cycle risks despite a higher 2026 profit outlook.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Omnicell highlights Titan XT and OmniSphere momentum, and raises profit outlook, while customer approval timing weighs on product bookings.
Omnicell NASDAQ: OMCL reported second-quarter 2026 revenue at the high end of its prior outlook and profitability above expectations, while widening its full-year product bookings range to reflect uncertainty in the timing of customer purchasing decisions for large medication-management platform investments.
Omnicell, Inc. (OMCL) Q2 2026 Earnings Call Transcript
Omnicell (OMCL) came out with quarterly earnings of $0.94 per share, beating the Zacks Consensus Estimate of $0.48 per share. This compares to earnings of $0.45 per share a year ago.
FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell Announces Second Quarter 2026 Financial Results.
OMCL heads into Q2 earnings with OmniSphere adoption, Connected Devices execution and recurring revenue growth ahead of July 30 results.
Omnicell is advancing its autonomous pharmacy vision and expanding SaaS offerings, but tariffs and fierce competition could test its growth path.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on OMCL and any ticker you trade — then tracks every position and per-strategy win rate.
